How to Manage Estrogen on TRT

Your testosterone goes in, and some of it becomes estrogen. That is not a malfunction. That is the system working exactly as designed, and the enzyme doing that conversion is called aromatase, which is a cytochrome P450 enzyme that takes testosterone and chemically restructures it into estradiol through a three-step reaction. In men, roughly 80% of circulating estradiol comes from this peripheral conversion happening in your tissues, with only about 20% coming from the testes directly. So when a provider sees elevated estradiol on your labs and reaches for anastrozole to block that enzyme, they are not fixing a broken system. They are suppressing a normal one.

The question that almost never gets asked is what is driving the conversion up in the first place.

Aromatase does not run at a fixed rate. It responds to its environment, and two things control how much conversion happens: how much enzyme you have, and how much substrate you are feeding it. Substrate means testosterone. Enzyme means the actual aromatase protein sitting in your tissues. Both of these can be pushed higher by specific, changeable factors, and understanding which factor is doing the pushing tells you exactly what to address.

Start with body fat. Aromatase is concentrated in adipose tissue, and the gene that codes for it in fat cells is activated by glucocorticoids, inflammatory cytokines like TNF-alpha, and a specific promoter region called promoter I.4. When men carry more body fat, they have more of this enzyme expressed in more tissue, which means every single milligram of testosterone in their bloodstream has more enzyme available to convert it. Men with obesity show measurably increased aromatase expression in adipose tissue compared to lean men, and the feedback loop compounds: more fat means more estrogen, and elevated estrogen can promote further fat storage.

Now add the injection frequency problem, which is where most TRT estrogen issues actually start.

Testosterone cypionate has an elimination half-life of roughly 4.5 days and a mean residence time of about 8.5 days. When you inject a full week's dose at once, testosterone peaks within 24 to 48 hours and then falls steadily through the rest of the week, creating a significant peak-to-trough swing. Estradiol trails that testosterone peak by roughly one to two days, so it spikes around day three or four. Because aromatase conversion is substrate-driven, meaning more testosterone available means more conversion happening, that large testosterone peak floods the enzyme with raw material and produces a corresponding estradiol spike. By day seven you are in a trough. The next injection restarts the cycle.

Splitting that same weekly dose into two injections reduces peak-to-trough variance by approximately 30%. Daily injection reduces it further, approaching the body's natural production pattern of around six to seven milligrams per day. The total testosterone you are putting in has not changed. But the peaks are smaller, which means the substrate bolus hitting aromatase at any one moment is smaller, which means the estradiol spikes are reduced. The total weekly estrogen production may be similar, but the spikes are what drive the symptoms: water retention, nipple sensitivity, mood swings. Eliminating the spikes often eliminates the complaints, without touching the enzyme at all.

Beyond body fat and injection frequency, alcohol directly increases aromatase activity. Insulin resistance affects both aromatase expression and something called SHBG, which is sex hormone-binding globulin, a protein that binds testosterone and makes it unavailable for conversion. When SHBG is low, more free testosterone is available, more substrate is in circulation, and more conversion follows. Cortisol drives aromatase expression through the same promoter I.4 pathway that body fat uses, which means chronic stress and poor sleep both push conversion upward through the inflammation and glucocorticoid response they generate. Your genetics also determine baseline CYP19A1 expression, meaning two men on the exact same dose can convert at genuinely different rates.

So the clinical trap looks like this. A man starts weekly testosterone injections. His estradiol comes back elevated. The clinic prescribes anastrozole. Aromatase is now suppressed. His estrogen falls, possibly below range. And now he has joint pain, declining erectile function, depression, and is gaining fat, not because his testosterone is low, but because his estrogen is too low.

The 2013 Finkelstein study in the New England Journal of Medicine demonstrated exactly this. Four hundred healthy men aged 20 to 50 had their natural production suppressed with goserelin, then received varying testosterone doses with or without anastrozole to block aromatization. When estrogen was blocked while testosterone was kept present, sexual desire declined significantly (P less than 0.001) and erectile function declined significantly (P equals 0.022). Subcutaneous fat area increased two to three times in groups with suppressed estrogen. The study isolated estrogen's independent role precisely because testosterone was still there. The estrogen was gone, and the symptoms followed.

A separate 12-month double-blind trial from 2009 gave 69 older men either 1 mg anastrozole daily or placebo. Estradiol fell only modestly, from 15 to 12 pg/mL, roughly a 20% drop. That was enough to produce a statistically significant decrease in spinal bone mineral density (P equals 0.0014) over 12 months. Estradiol levels are more strongly correlated with bone density and bone turnover in adult men than testosterone levels are, which means suppressing estrogen to manage TRT symptoms carries a real long-term cost that does not show up in short-term labs.

The practical path starts with getting an accurate baseline. Standard immunoassay estradiol tests cross-react with other steroids in men and can give inaccurate readings, so the test you want is called LC-MS/MS, which stands for liquid chromatography tandem mass spectrometry, and it is the gold standard for measuring male estradiol. Most men on standard TRT doses are targeting somewhere around 20 to 35 pg/mL, with higher ranges, up to 40 to 60, being acceptable at higher doses if the person is feeling well.

From there, the variables to address in order are injection frequency first, total dose second, body composition third, and then the lifestyle factors: sleep, alcohol, insulin sensitivity, and stress. An aromatase inhibitor is not FDA-approved for use in men, it is prescribed entirely off-label in the TRT context, and it introduces an oscillating variable into a system that was already being managed with a single drug.

The deeper point is that estrogen on TRT is not the enemy. It is a signal. And the signal is telling you something specific about where your conversion rate is coming from.

---

References

1. Finkelstein JS, Lee H, Burnett-Bowie SA, et al. 2013. Gonadal Steroids and Body Composition, Strength, and Sexual Function in Men. New England Journal of Medicine, 36911, 1011-1022. Source
2. Burnett-Bowie SM, McKay EA, Lee H, Leder BZ. 2009. Effects of Aromatase Inhibition on Bone Mineral Density and Bone Turnover in Older Men with Low Testosterone Levels. Journal of Clinical Endocrinology and Metabolism, 9412, 4785-4792. Source
3. Pastuszak AW, et al. 2022. Pharmacokinetics of Testosterone Cypionate Delivered via Subcutaneous Autoinjector. Andrology. Source
4. Chand AL, et al. (2015). Weight gain and inflammation regulate aromatase expression in male adipose tissue. Journal of Steroid Biochemistry and Molecular Biology.
5. Bhasin S, Brito JP, Cunningham GR, et al. (2018). Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. JCEM, 103(5), 1715-1744.

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness